Scripscan:Wyeth Ltd
cmp:670
Code:500095
Story:Wyeth is the sixth largest pharma MNC in India. It has set up a state-of-art manufacturing facility at Goa.The company has achieved market leadership in the Folic acid, Oral contraceptives and Depilatory cream segment.Its product portfolio includes therapeutic segments of Anti - Infectives, Vaccines, Oral contraceptives and Hormone Therapy.Wyeth Ltd. reported disappointing set of numbers for the second quarter ended 30th September 2009. The company reported a marginal dip of 1.7% in its top-line from Rs 1,146.7 million for Q1FY10 to Rs 1,127.5 million for Q2FY10. With a Q-o-Q decline of 45.4% in Other Income & increase in Interest burden by close to 160%, Wyeth reported a Q-o-Q dip of 13.6% in its bottomline from Rs 291.5 million for Q1FY10 to Rs 261.9 million for Q2FY10. We continue to remain positive about the future prospects of Wyeth Ltd. Even though the quarterly numbers do not look promising, we believe that the company would be able to deliver better results going forward. At CMP of Rs 670, the scrip trades at 12.6x FY10E earnings of Rs. 52.8. Maintain BUY on dips.
Friday, November 6, 2009
Important Disclaimer&Privacy policy
This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com
Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
